2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Head & Neck
1
Gynecologic
1
Conditions
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Interventions
Specimen Handling
454
Magnetic Resonance Spectroscopy
347
pembrolizumab
289
Biopsy
244
Carboplatin
230
Cisplatin
194
Cyclophosphamide
186
Paclitaxel
164
Nivolumab
154
Gemcitabine
151
Radiotherapy
125
Bevacizumab
124
Dexamethasone
113
fludarabine
100
Pemetrexed
99
Fluorouracil
94
Doxorubicin
92
durvalumab
91
Radiation
91
Docetaxel
91
venetoclax
89
Rituximab
88
Oxaliplatin
88
atezolizumab
87
Leucovorin
79
Capecitabine
76
Prednisone
75
Lenalidomide
70
Etoposide
69
X-Rays
66
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Imlunestrant
×
30 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT07287098
2026-05-22
preEMBER
Eli Lilly and Company
Phase 2
Not yet recruiting
600 enrolled